Exelixis (EXEL) Interest Coverage Ratio: History & Chart

Exelixis, Inc.(EXEL)

Biotechnology · Alameda, CA

$58.85+0.46 (+0.79%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Exelixis, Inc.

Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.

Alameda, CA

1,077 employees

www.exelixis.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael Morrissey

View full financials

EXEL Interest Coverage Ratio Metrics

INTEREST COVERAGE RATIO

6.37x

INTEREST COVERAGE RATIO AVG TTM

3.71x

INTEREST COVERAGE RATIO AVG 3Y

-0.27x

INTEREST COVERAGE RATIO AVG 5Y

-3.42x

INTEREST COVERAGE RATIO AVG 10Y

-3.98x

INTEREST COVERAGE RATIO AVG 15Y

N/A

INTEREST COVERAGE RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

+71.69%

CURRENT VS 3Y AVG

+2422.57%

CURRENT VS 5Y AVG

+285.95%

CURRENT VS 10Y AVG

+260.08%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

1.02x

median of 200 covered companies

CURRENT VS SECTOR MEDIAN

+527.20%

vs the sector median at left

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
Exelixis, Inc. (EXEL)	$14.79B	6.37x	3.71x	-0.27x	-3.42x
Tempus AI, Inc. (TEM)vs ›	$14.64B	-3.60x	N/A	N/A	N/A
Charles River Laboratories International, Inc. (CRL)vs ›	$14.97B	4.74x	3.27x	5.51x	5.84x
Solventum Corporation (SOLV)vs ›	$15.24B	6.29x	4.55x	4.55x	4.55x
Ascendis Pharma A/S (ASND)vs ›	$14.16B	-1.69x	367.76x	367.76x	367.76x
BridgeBio Pharma, Inc. (BBIO)vs ›	$12.95B	-10.72x	N/A	N/A	N/A
ICON Public Limited Company (ICLR)vs ›	$12.89B	5.38x	5.00x	4.08x	8.08x
Baxter International Inc. (BAX)vs ›	$12.52B	-1.06x	0.71x	2.65x	6.89x
Penumbra, Inc. (PEN)vs ›	$12.49B	144.35x	102.58x	62.73x	62.73x
Medpace Holdings, Inc. (MEDP)vs ›	$17.32B	N/A	393.08x	892.58x	554.26x

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

Exelixis, Inc. (EXEL)

$14.79B

6.37x

3.71x

-0.27x

-3.42x

Tempus AI, Inc. (TEM)vs ›

$14.64B

-3.60x

N/A

Charles River Laboratories International, Inc. (CRL)vs ›

$14.97B

4.74x

3.27x

5.51x

5.84x

Solventum Corporation (SOLV)vs ›

$15.24B

6.29x

4.55x

Ascendis Pharma A/S (ASND)vs ›

$14.16B

-1.69x

367.76x

BridgeBio Pharma, Inc. (BBIO)vs ›

$12.95B

-10.72x

N/A

ICON Public Limited Company (ICLR)vs ›

$12.89B

5.38x

5.00x

4.08x

8.08x

Baxter International Inc. (BAX)vs ›

$12.52B

-1.06x

0.71x

2.65x

6.89x

Penumbra, Inc. (PEN)vs ›

$12.49B

144.35x

102.58x

62.73x

Medpace Holdings, Inc. (MEDP)vs ›

$17.32B

N/A

393.08x

892.58x

554.26x

Interest Coverage Ratio FAQ

What is the interest coverage ratio for Exelixis, Inc. (EXEL)?

The interest coverage ratio for EXEL stock is 6.37x.

Is Exelixis, Inc.'s interest coverage ratio high or low?

The interest coverage ratio of 6.37x is 286% above its 5-year average of -3.42x, near the high end of its 5-year range (-5.53x–8.67x).

What is the TTM average interest coverage ratio for Exelixis, Inc. (EXEL)?

The TTM average interest coverage ratio for EXEL stock is 3.71x.

What is the 3Y average interest coverage ratio for Exelixis, Inc. (EXEL)?

The 3Y average interest coverage ratio for EXEL stock is -0.27x.

What is the 5Y average interest coverage ratio for Exelixis, Inc. (EXEL)?

The 5Y average interest coverage ratio for EXEL stock is -3.42x.

What is the 10Y average interest coverage ratio for Exelixis, Inc. (EXEL)?

The 10Y average interest coverage ratio for EXEL stock is -3.98x.

DATE	INTEREST COVERAGE RATIO
2017-06-30	6.37x
2017-03-31	4.57x
2016-12-31	8.67x
2016-09-30	0.93x
2016-07-01	-1.99x
2016-04-01	-3.96x
2015-12-31	-2.58x
2015-10-02	-2.97x
2015-07-03	-2.59x
2015-04-03	-1.83x
2014-12-31	-3.70x
2014-09-26	-4.20x
2014-06-27	-5.11x
2014-03-28	-5.53x
2013-12-31	-5.12x
2013-09-27	-4.89x
2013-06-28	-4.56x
2013-03-29	-3.08x
2012-12-31	-3.71x
2012-09-30	-3.31x
2012-06-29	-8.00x
2012-03-30	-5.57x
2011-12-31	12.86x
2011-09-30	19.24x
2011-07-01	-4.32x
2011-04-01	-6.02x
2010-12-31	-3.56x
2010-10-01	-1.03x
2010-07-02	-38.08x
2010-04-02	-77.54x
2009-12-31	-4.80x
2009-10-02	-7.93x
2009-07-03	-17.95x
2009-04-03	-17.38x
2008-09-26	-20.55x
2008-06-27	-38.82x
2008-03-28	-48.62x

DATE

INTEREST COVERAGE RATIO

2017-06-30

6.37x

2017-03-31

4.57x

2016-12-31

8.67x

2016-09-30

0.93x

2016-07-01

-1.99x

2016-04-01

-3.96x

2015-12-31

-2.58x

2015-10-02

-2.97x

2015-07-03

-2.59x

2015-04-03

-1.83x

2014-12-31

-3.70x

2014-09-26

-4.20x

2014-06-27

-5.11x

2014-03-28

-5.53x

2013-12-31

-5.12x

2013-09-27

-4.89x

2013-06-28

-4.56x

2013-03-29

-3.08x

2012-12-31

-3.71x

2012-09-30

-3.31x

2012-06-29

-8.00x

2012-03-30

-5.57x

2011-12-31

12.86x

2011-09-30

19.24x

2011-07-01

-4.32x

2011-04-01

-6.02x

2010-12-31

-3.56x

2010-10-01

-1.03x

2010-07-02

-38.08x

2010-04-02

-77.54x

2009-12-31

-4.80x

2009-10-02

-7.93x

2009-07-03

-17.95x

2009-04-03

-17.38x

2008-09-26

-20.55x

2008-06-27

-38.82x

2008-03-28

-48.62x

Interest Coverage Ratio: 6.37x

EXEL Interest Coverage Ratio

EXEL Average Interest Coverage Ratio Chart

EXEL Current vs Average Interest Coverage Ratio Chart

EXEL Interest Coverage Ratio Metrics

EXEL Competitors' Interest Coverage Ratio

Financial Health Indicators

Interest Coverage Ratio Formula & Definition

Interest Coverage Ratio FAQ

EXEL Interest Coverage Ratio History

Related Metrics